August 19, 2015

Odan Laboratories Ltd, a fast growing Canadian Pharmaceutical Company, is proud to announce that it has acquired Asmacure Ltée , a Quebec City based clinical-stage Biopharmaceutical Company, for the development and commercialization of its lead compound ASM-024 .

Asmacure’s lead patented compound, ASM-024 , has a novel multi-functional modulatory activity on nicotinic and muscarinic receptors. ASM-024 has also demonstrated the capabilities of anti-inflammation, broncho -protection, and smooth muscle relaxation in pre-clinical asthma models. In addition, ASM-024 has shown promising results in the inhibition of two different cancer cell lines. Odan plans to further explore the role of ASM-024 in the potential treatment of selected cancer indications.

“With the acquisition of Asmacure, Odan is poised to expand and diversify its R&D activities.” expressed Howard Kaminsky, president of Odan Laboratories Ltd. “We are confident in the potential of Asmacure’s ASM-024 to be therapeutically important and profitable for Odan.”